Resveratrol overcomes cellular resistance to vemurafenib through dephosphorylation of akt in BRAF-mutated melanoma cells
H Luo, M Umebayashi, K Doi, T Morisaki… - Anticancer …, 2016 - ar.iiarjournals.org
Background/Aim: The serine/threonine-protein kinase B-Raf (BRAF) V600E mutant
(BRAFV600E) inhibitor vemurafenib, has improved clinical outcomes for patients with …
(BRAFV600E) inhibitor vemurafenib, has improved clinical outcomes for patients with …
[PDF][PDF] Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells
HAO LUO, M UMEBAYASHI, K DOI… - ANTICANCER …, 2016 - researchgate.net
Background/Aim: The serine/threonine-protein kinase B-Raf (BRAF) V600E mutant
(BRAFV600E) inhibitor vemurafenib, has improved clinical outcomes for patients with …
(BRAFV600E) inhibitor vemurafenib, has improved clinical outcomes for patients with …
Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
H Luo, M Umebayashi, T Morisaki, S Shirasawa… - Anticancer …, 2016 - europepmc.org
Materials and methods A vemurafenib-resistant human metastatic melanoma cell line
positive for the BRAF V600E mutation was established. The anti-tumorigenic effects of …
positive for the BRAF V600E mutation was established. The anti-tumorigenic effects of …
Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells
H Luo, M Umebayashi, K Doi, T Morisaki… - Anticancer …, 2016 - pubmed.ncbi.nlm.nih.gov
Background/aim The serine/threonine-protein kinase B-Raf (BRAF) V600E mutant (BRAF
(V600E)) inhibitor vemurafenib, has improved clinical outcomes for patients with BRAF …
(V600E)) inhibitor vemurafenib, has improved clinical outcomes for patients with BRAF …
[PDF][PDF] Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells
HAO LUO, M UMEBAYASHI, K DOI… - ANTICANCER …, 2016 - ar.iiarjournals.org
Background/Aim: The serine/threonine-protein kinase B-Raf (BRAF) V600E mutant
(BRAFV600E) inhibitor vemurafenib, has improved clinical outcomes for patients with …
(BRAFV600E) inhibitor vemurafenib, has improved clinical outcomes for patients with …
Resveratrol overcomes cellular resistance to vemurafenib through dephosphorylation of AKT in BRAF-mutated melanoma cells.
H Luo, M Umebayashi, K Doi, T Morisaki, S Shirasawa… - 2016 - cabidigitallibrary.org
Abstract Background/Aim: The serine/threonine-protein kinase B-Raf (BRAF) V600E mutant
(BRAFV600E) inhibitor vemurafenib, has improved clinical outcomes for patients with …
(BRAFV600E) inhibitor vemurafenib, has improved clinical outcomes for patients with …
[引用][C] Resveratrol overcomes cellular resistance to vemurafenib through dephosphorylation of AKT in BRAF‐mutated melanoma cells
H Luo - Anticancer Res, 2016 - cir.nii.ac.jp
Resveratrol overcomes cellular resistance to vemurafenib through dephosphorylation of AKT in
BRAF‐mutated melanoma cells | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
BRAF‐mutated melanoma cells | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …